
PASS Study Report

Active substance Aclidinium bromide

Product reference D6560R00004

Version number 1.0

Date 01 June 2021

Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Acute Myocardial Infarction and Stroke

RTI Health Solutions has obtained from the CPRD a waiver for the masking of cells with less than 5 events for regulatory submission reports (29 Oct 2018)

This version of the report cannot be disseminated beyond the regulatory reviewers. Small cell counts need to be suppressed if the regulators wish to publish or disseminate in the interest of transparency. All small cell counts < 5 in this report have been highlighted clearly with a note that these would have to be redacted if shared outside the regulatory environment.

Marketing Authorisation Holder(s)

Marketing authorisation holder(s)	AstraZeneca AB SE-151 85 Södertälje Sweden
MAH contact person	<div>██████████</div> <div>Regulatory Affairs Director</div> <div>Email: <div>████████████████████████████████████████</div></div>

GENUAIR™ is a trademark of the AstraZeneca group of companies. EKLIRA™, BRETARIS™, DUAKLIR™, and BRIMICA™ are trademarks of Almirall S.A.

This document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.

Approved by:

Principal Investigator, Cristina Rebordosa,
MD, PhD

Date

PASS INFORMATION

Title	Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Acute Myocardial Infarction and Stroke
Version identifier of the final study report	1.0
Date of last version of the final study report	01 June 2021
EU PAS register number	ENCEPP/SDPP/13616; 23 May 2014
Active substance	Aclidinium bromide (ATC code: R03BB05) Aclidinium bromide/formoterol fumarate dihydrate (ATC code: R03AL05)
Medicinal product	Eklira® Genuair®/Bretaris® Genuair® Duaklir® Genuair®/Brimica® Genuair®
Product reference	Eklira® Genuair®: H0002211 Bretaris® Genuair®: H0002706 Duaklir® Genuair®: H0003745 Brimica® Genuair®: H0003969
Procedure number	Eklira® Genuair®: EMEA/H/C/002211 Bretaris® Genuair®: EMEA/H/C/002706 Duaklir® Genuair®: EMEA/H/C/003745 Brimica® Genuair®: EMEA/H/C/003969
Marketing authorisation holder(s)	AstraZeneca AB SE-151 85 Södertälje Sweden
Joint PASS	No

Research question and objectives	<p>The overall objective of this post-authorisation safety study (PASS) is to evaluate the potential cardiovascular safety concerns and all-cause mortality described in the risk management plan for acclidinium bromide through sequential, cohort substudies for each endpoint of interest. Specific objectives are as follows:</p> <ul style="list-style-type: none">• To compare the risk of acute myocardial infarction, including community coronary heart disease death; stroke, including community cerebrovascular disease death; composite endpoint of major adverse cardiac events; congestive heart failure; and all-cause mortality in patients with chronic obstructive pulmonary disease (COPD) initiating treatment with acclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and fixed-dose combination with formoterol, when available) and other inhaled COPD medications with the risk in patients with COPD initiating treatment with long-acting beta2-agonists (LABAs).• To compare the risk of acute myocardial infarction, stroke, composite endpoint of major adverse cardiac events, congestive heart failure, and all-cause mortality in patients with COPD initiating treatment with acclidinium bromide (monotherapy; concomitant with formoterol not in fixed-dose combination; and fixed-dose combination with formoterol, when available) with the risk in patients with COPD initiating other inhaled treatments for COPD.• To evaluate the effect of duration of each of the study medications on the risk of each individual endpoint. <p>This report addresses the acute myocardial infarction, stroke, and composite of major adverse cardiac events components of the PASS programme among users of acclidinium bromide (monotherapy or concomitant use with formoterol not in fixed-dose combination) and among users of acclidinium/formoterol.</p> <p>New users of the fixed-dose combination of acclidinium/formoterol are also included as a separate cohort for evaluation. A new additional endpoint of cardiac arrhythmias will be evaluated for this cohort.</p>
-----------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

	<p>This report also includes the following information:</p> <ul style="list-style-type: none">• Results of the descriptive analyses of the incidence rates for cardiac arrhythmias and recalculation of the sample size for this study endpoint, per the PASS protocol milestones.• Results of the descriptive analyses of the incidence rates for congestive heart failure and all-cause mortality among users of aclidinium/formoterol and an evaluation of potential differences with the incidence rates among users of aclidinium bromide.
Country(-ies) of study	United Kingdom: the Clinical Practice Research Datalink (CPRD)
Author	Cristina Rebordosa, MD, PhD, RTI Health Solutions [REDACTED] MD, MPH, FISPE, RTI Health Solutions

APPROVAL PAGE: RTI HEALTH SOLUTIONS

Project Title: Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Acute Myocardial Infarction and Stroke

Authors: Cristina Rebordosa, MD, PhD, and [REDACTED] MD, MPH,
FISPE

Report version: 1.0

Date: 01 June 2021

The following people have reviewed the report and give their approval:

Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP
Vice President and Global Head of Epidemiology
RTI Health Solutions

Date

APPROVAL PAGE: ASTRAZENECA—CLINICAL LEAD

Project Title: Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Acute Myocardial Infarction and Stroke

Authors: Cristina Rebordosa, MD, PhD, and [REDACTED], MD, MPH,
FISPE

Report version: 1.0

Date: 01 June 2021

The following people have reviewed the report and give their approval:

[REDACTED], MD
Executive Director, Clinical Development,
Global Clinical Head, Eklira & Duaklir Franchise

Date

APPROVAL PAGE: ASTRAZENECA—QPPV

Project Title: Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Acute Myocardial Infarction and Stroke

Authors: Cristina Rebordosa, MD, PhD and [REDACTED], MD, MPH,
FISPE

Report version: 1.0

Date: 01 June 2021

The following people have reviewed the report and give their approval:

[REDACTED]
AstraZeneca Deputy EU QPPV
as delegated by [REDACTED],
AstraZeneca EU QPPV

Date

TABLE OF CONTENTS

PASS INFORMATION	2
TABLE OF CONTENTS.....	8
LIST OF APPENDICES.....	10
LIST OF TABLES.....	10
LIST OF FIGURES	11
1 ABSTRACT.....	13
2 LIST OF ABBREVIATIONS.....	18
3 INVESTIGATORS	20
4 OTHER RESPONSIBLE PARTIES.....	20
5 MILESTONES.....	21
6 RATIONALE AND BACKGROUND.....	22
7 RESEARCH QUESTION AND OBJECTIVES.....	23
8 AMENDMENTS AND UPDATES.....	24
9 RESEARCH METHODS	24
9.1 Study design.....	24
9.2 Setting	24
9.3 Subjects	25
9.3.1 Inclusion criteria	25
9.3.2 Exclusion criteria	26
9.4 Variables	28
9.4.1 Exposures	28
9.4.2 Study endpoints.....	29
9.4.3 Confounding factors.....	32
9.5 Data sources and measurement.....	34
9.6 Bias.....	35
9.7 Study size	35
9.8 Data transformation.....	37
9.9 Statistical methods	37
9.9.1 Main summary measures	37
9.9.2 Main statistical methods.....	38
9.9.3 Missing values.....	41
9.9.4 Sensitivity analysis.....	41
9.9.5 Amendments to the statistical analysis plan	42
9.10 Quality control	42
10 RESULTS	42

10.1	Participants.....	42
10.1.1	Cohort attrition.....	42
10.1.2	Duration of use.....	45
10.2	Descriptive data.....	45
10.2.1	Baseline characteristics by study medication.....	45
10.2.2	COPD severity	48
10.2.3	Medical history at the start date	48
10.2.4	Charlson Comorbidity Index.....	51
10.2.5	Use of study medications before the start date	51
10.2.6	Use of other medications before the start date	54
10.2.7	Use of health care resources before the start date	57
10.2.8	Summary of baseline characteristics.....	60
10.3	Outcome data	60
10.3.1	Acute myocardial infarction, stroke, and MACE events	60
10.3.2	All-cause mortality and heart failure	61
10.3.3	Univariate association of risk factors with acute myocardial infarction and stroke	61
10.4	Main results.....	62
10.4.1	Incidence rates and incidence rate ratios for AMI, stroke, and MACE for current, recent, and past use of each study medication versus LABA	62
10.4.2	Incidence rates and incidence rate ratios for AMI, stroke, and MACE for current use of study medications versus acclidinium bromide	65
10.4.3	Incidence rates and incidence rate ratios for AMI, stroke, and MACE for current single and current multiple use of study medications versus LABA.....	68
10.4.4	Incidence rates and incidence rate ratios for AMI, stroke, and MACE for short and long duration of current use of study medications versus LABA	71
10.4.5	Subgroup analyses.....	74
10.4.6	Sensitivity analyses	78
10.5	Other analyses	82
10.5.1	All-cause mortality and heart failure	82
10.5.2	Cardiac arrhythmias	83
10.6	Adverse events/adverse reactions	83
11	DISCUSSION	83
11.1	Key results.....	83
11.2	Limitations	84
11.3	Interpretation.....	86
12	GENERALISABILITY	88
13	OTHER INFORMATION	88
14	CONCLUSION.....	88
15	REFERENCES.....	88

LIST OF APPENDICES

Appendix A	List of stand-alone documents.....	94
Appendix B	Study size re-estimation and feasibility of the aclidinium PASS substudy on cardiac arrhythmias.....	95
Appendix C	ICD-10 codes and terms used to define the study endpoints.....	101

LIST OF TABLES

Table 1.	Classification of COPD severity using the GOLD 2016 definition	34
Table 2.	Approximate number of patients with COPD exposed to aclidinium bromide for 1 year to have an 80% probability of detecting a relative risk of 1.5, 2, 2.5, and 3 (original study size calculations)	36
Table 3.	Approximate number of aclidinium bromide users needed for AMI and stroke substudies to have an 80% probability of detecting risk ratios of 1.5, 2, 2.5, and 3 or an upper limit of the 95% confidence interval below 1.5, 2, 2.5, and 3 (2019 estimation)	37
Table 4.	Cohort attrition for new users of aclidinium bromide and other study medications	44
Table 5.	Distribution of demographic and lifestyle habits at the start date, by study medication	46
Table 6.	Medical history at any time before the start date, by study medication	49
Table 7.	Prior use of respiratory medications within 12 months before the start date, by study medication.....	53
Table 8.	Use of other medications within 12 months before the start date, by study medication	55
Table 9.	Distribution of health care resource utilisation within 12 months before the start date, by study medication	58
Table 10.	Number of outcome events during current use, by outcome and study medication	61
Table 11.	Adjusted incidence rate ratios for AMI and stroke comparing current use of aclidinium bromide and current use of aclidinium/formoterol with current use of LABA, main analysis and adjusted by propensity score deciles before and after trimming	81
Table 12.	Crude and adjusted incidence rate ratios for all-cause mortality and heart failure.....	82

Table 13.	Crude incidence rates for cardiac arrhythmias among users of LABA (n = 11,653): HES primary discharge code and/or ONS identification	97
Table 14.	Number of aclidinium/formoterol users needed for the cardiac arrhythmias substudy to have an 80% probability of detecting risk ratios of 1.5, 2, 2.5, and 3 or an upper limit of the 95% confidence interval below 1.5, 2, 2.5, and 3 (2021 estimation)	98

LIST OF FIGURES

Figure 1.	Overview of study design and eligibility criteria for the study cohorts	27
Figure 2.	Distribution of COPD severity, by study medication	48
Figure 3.	Distribution of the Charlson Comorbidity Index score at the start date, by study medication	51
Figure 4.	Prior use of study medications, by study medication	52
Figure 5.	Adjusted incidence rate ratios for AMI for current, recent, and past use of each study medication versus LABA	63
Figure 6.	Adjusted incidence rate ratios for stroke for current, recent, and past use of each study medication versus LABA	64
Figure 7.	Adjusted incidence rate ratios for MACE for current, recent, and past use of each study medication versus LABA	65
Figure 8.	Adjusted incidence rate ratios for AMI for current use of each study medication versus aclidinium bromide	66
Figure 9.	Adjusted incidence rate ratios for stroke for current use of each study medication versus aclidinium bromide	67
Figure 10.	Adjusted incidence rate ratios for MACE for current use of each study medication versus aclidinium bromide	68
Figure 11.	Adjusted incidence rate ratios for AMI for current single and current multiple use of each study medication versus current single use of LABA	69
Figure 12.	Adjusted incidence rate ratios for stroke for current single and current multiple use of each study medication versus current single use of LABA	70
Figure 13.	Adjusted incidence rate ratios for MACE for current single and current multiple use of each study medication versus current single use of LABA	71
Figure 14.	Adjusted incidence rate ratios for AMI by short and long duration of current use of each study medication versus short and long duration of current use of LABA	72

Figure 15.	Adjusted incidence rate ratios for stroke by short and long duration of current use of each study medication versus short and long duration of current use of LABA	73
Figure 16.	Adjusted incidence rate ratios for MACE by short and long duration of current use of each study medication versus short and long duration of current use of LABA	74
Figure 17.	Subgroup and sensitivity analysis of AMI: current use of each study medication versus current use of LABA	76
Figure 18.	Subgroup and sensitivity analysis of stroke: current use of each study medication versus current use of LABA	77
Figure 19.	Distribution of propensity scores among users of LABA and users of acridinium bromide	79
Figure 20.	Distribution of propensity scores among users of LABA and users of acridinium/formoterol	80

1 ABSTRACT

Title: Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Acute Myocardial Infarction and Stroke

Version: 1.0, 01 June 2021

Authors: Cristina Rebordosa, MD, PhD, and [REDACTED], MD, MPH, FISPE

Keywords: aclidinium bromide; LAMA; chronic obstructive pulmonary disease; myocardial infarction; stroke; database study

Rationale and background: Aclidinium bromide is an inhaled long-acting anticholinergic (LAMA) approved in Europe in 2012 as maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A series of substudies were planned to evaluate potential cardiovascular safety concerns identified in the aclidinium risk management plan, to address cardiovascular concerns associated with LAMA use. The first and second substudies did not observe an increased risk of all-cause mortality or congestive heart failure associated with the use of aclidinium. Results of the third and fourth substudies, which focused on the risk of acute myocardial infarction (AMI) and stroke, are presented in the current report. This report also includes (1) the descriptive analysis of incidence rates for cardiac arrhythmias (to be evaluated in a future substudy) and recalculation of the study size for this endpoint, and (2) the descriptive analysis of incidence rates for all-cause mortality and congestive heart failure in order to evaluate if there are differences between the incidence rates for these endpoints in aclidinium users and aclidinium/formoterol users.

Research question and objectives: (1) To compare the risk of AMI and stroke in patients with COPD initiating treatment with aclidinium and other selected COPD medications with the risk in patients with COPD initiating treatment with long-acting beta2-agonists (LABAs). (2) To compare the risk of AMI and stroke between use of aclidinium and use of each of the selected COPD medications. (3) To evaluate the effect of duration of use. (4) To estimate the incidence rates for all-cause mortality and first-ever hospitalisation for heart failure among new users of aclidinium/formoterol in a fixed-dose combination and compare them with the incidence rates among new users of aclidinium bromide in the current study.

Study design: Non-interventional database cohort study of patients with COPD aged 40 years or older starting (new users) treatment with aclidinium, aclidinium/formoterol, tiotropium, other LAMA (glycopyrronium or umeclidinium), LAMA/LABA, LABA/inhaled corticosteroids (LABA/ICS), or LABA.

Setting: The primary care Aurum database of the Clinical Practice Research Datalink (CPRD) in the United Kingdom, from September 2012 through June 2019. The study included all practices where linkage was available to obtain information on date and cause of death from the Office for National Statistics (ONS) and information on hospitalisations from the Hospital Episode Statistics (HES) database.

Subjects and study size, including dropouts: A total of 18,112 new users of aclidinium were identified; 15,221 met eligibility criteria (84.0%) and 11,121 (61.4%) were included in the assessment of AMI and stroke endpoints for aclidinium. Similarly, a total of 7,621 new users of aclidinium/formoterol were identified; 6,701 met eligibility criteria (87.9%) and 4,804 (63.0%) were included in the assessment of AMI and stroke endpoints for aclidinium.

Variables and data sources: Exposure to the study medications was ascertained through prescription information recorded in the CPRD. The endpoint AMI was defined as hospitalisation for AMI, either non-fatal or fatal, plus out-of-hospital (“community”) coronary heart disease (CHD) deaths. Stroke was defined as acute stroke, either fatal (i.e., in-hospital deaths) or non-fatal, and included hospital admission and emergency department visit or referral to a specialist (neurologist) plus community cerebrovascular disease (CeVD) deaths. The composite endpoint of major adverse cardiac events (MACE) included the first occurrence of either AMI, stroke, community CHD death, or CeVD death. The main risk factors evaluated included age, sex, smoking, body mass index (BMI), COPD severity, comorbidity, comedications, and utilisation of health care resources. Crude incidence rates for hospitalisation for AMI and stroke were estimated for current use of each study medication. Crude and adjusted incidence rate ratios (IRRs) were estimated for current, recent, and past use of each study medication versus current use of LABA. Risks were also estimated for current single use and current multiple use and by duration of current use of the study medications. Several subgroup and sensitivity analyses were conducted.

Results: The study included 11,121 new users of aclidinium, 4,804 new users of aclidinium/formoterol, 56,198 new users of tiotropium, 23,856 new users of other LAMA, 17,450 new users of LAMA/LABA, 70,289 new users of LABA/ICS, and 13,716 new users of LABA. The distributions of age, sex, race, current smoking, BMI, alcohol abuse, and deprivation index were similar across the study medications. Severity category “D” (the most severe category) was more frequent in users of aclidinium (33.4%) and users of other LAMA (29.5%) than in users of LAMA/LABA (25.9%), tiotropium (24.7%), LABA/ICS (22.9%), and LABA (17.9%).

Crude incidence rates per 1,000 person-years for AMI, during current use, ranged from 8.7 for aclidinium/formoterol to 12.4 for LAMA/LABA. The crude incidence rates for stroke, during current use, ranged from 4.8 among users of aclidinium/formoterol to 7.2 among users of LAMA/LABA. Crude incidence rates per 1,000 person-years for MACE, during current use,

ranged from 13.5 for aclidinium/formoterol to 19.3 for LAMA/LABA. The adjusted IRRs for AMI, stroke, and MACE were around 1 for all study drugs when compared with current use of LABA (Abstract Table 1); therefore, no substantial differences were seen between medication groups.

Abstract Table 1. Risk of AMI and stroke associated with current use of the study medications versus current use of LABA

Current use	Number of events	Person-years	Crude incidence rate per 1,000 PY (95% CI)	Crude incidence rate ratio (95% CI)	Adjusted ^a incidence rate ratio (95% CI)
AMI					
LABA	144	13,681	10.53 (8.88-12.39)	1.0 (REF)	1.0 (REF)
Aclidinium	143	13,902	10.29 (8.67-12.12)	0.98 (0.78-1.23)	1.00 (0.76-1.31)
Aclidinium/formoterol	34	3,929	8.65 (5.99-12.09)	0.82 (0.57-1.19)	0.95 (0.60-1.52)
Tiotropium	967	85,368	11.33 (10.62-12.06)	1.08 (0.90-1.28)	1.06 (0.88-1.26)
Other LAMA	318	26,808	11.86 (10.59-13.24)	1.13 (0.93-1.37)	1.03 (0.81-1.29)
LAMA/LABA	187	15,027	12.44 (10.72-14.36)	1.18 (0.95-1.47)	1.23 (0.91-1.67)
LABA/ICS	1,292	118,145	10.94 (10.35-11.55)	1.04 (0.87-1.23)	1.03 (0.86-1.22)
Stroke					
LABA	93	13,682	6.80 (5.49-8.33)	1.0 (REF)	1.0 (REF)
Aclidinium	83	13,902	5.97 (4.76-7.40)	0.88 (0.65-1.18)	0.86 (0.62-1.18)
Aclidinium/formoterol	19	3,937	4.83 (2.91-7.54)	0.71 (0.43-1.16)	0.64 (0.39-1.06)
Tiotropium	587	85,463	6.87 (6.32-7.45)	1.01 (0.81-1.26)	1.02 (0.81-1.27)
Other LAMA	171	26,793	6.38 (5.46-7.41)	0.94 (0.73-1.21)	0.89 (0.69-1.17)
LAMA/LABA	108	15,023	7.19 (5.90-8.68)	1.06 (0.80-1.40)	0.95 (0.71-1.26)
LABA/ICS	801	118,280	6.77 (6.31-7.26)	1.00 (0.80-1.23)	1.02 (0.82-1.26)
MACE					
LABA	234	13,583	17.23 (15.09-19.58)	1.0 (REF)	1.0 (REF)
Aclidinium	221	13,810	16.00 (13.96-18.26)	0.93 (0.77-1.12)	0.93 (0.75-1.16)
Aclidinium/formoterol	53	3,913	13.54 (10.15-17.72)	0.79 (0.58-1.06)	0.94 (0.64-1.37)
Tiotropium	1,523	84,706	17.98 (17.09-18.91)	1.04 (0.91-1.20)	1.04 (0.90-1.20)
Other LAMA	484	26,628	18.18 (16.59-19.87)	1.06 (0.90-1.23)	1.03 (0.86-1.24)
LAMA/LABA	289	14,948	19.33 (17.17-21.70)	1.12 (0.94-1.33)	1.24 (0.97-1.59)
LABA/ICS	2,055	117,149	17.54 (16.79-18.32)	1.02 (0.89-1.17)	1.02 (0.89-1.17)

AMI = acute myocardial infarction; CHD = coronary heart disease; CI = confidence interval; ICS = inhaled corticosteroid; LABA = long-acting beta2-agonist; LAMA = long-acting anticholinergic; MACE = major adverse cardiovascular event; PY = person-years; REF = reference category.

Note: The number of events and person-years for current use of LABA (reference category) differed across the study medications. Current users of both LABA and the specific study medication of interest were excluded from each corresponding analysis.

^a For AMI, the models were adjusted by age; sex; COPD severity; calendar period; smoking; history of CHD; asthma; heart failure; number of prescriptions for respiratory medications in the 12 months prior to the start date; and use of LABA /ICS, LAMA/LABA, ICS, mucolytics, lipid-lowering drugs, beta-blockers, and vaccines in the 12 months prior to the start date. For stroke, the models were adjusted by age; sex; COPD severity; history of cerebrovascular disease; arrhythmias; asthma; heart failure; number of prescriptions for respiratory medications in the 12 months prior to the start date; and use of LABA, mucolytics, and oral glucocorticoids in the 12 months prior to the start date. For MACE, the models were adjusted by age; sex; COPD severity; calendar period; smoking; history of CHD; cerebrovascular disease; arrhythmias; heart failure; asthma; number of prescriptions for respiratory medications in the 12 months prior to the start date; and prior use of LABA, LABA/ICS, LAMA/LABA, ICS, mucolytics, oral glucocorticoids, beta-blockers, lipid-lowering drugs, and vaccines in the 12 months prior to the start date.

Comparing each study medication to LABA, adjusted IRRs for AMI and MACE for recent and past use and the adjusted IRRs for stroke for past use were similar to those observed for current use. The adjusted IRRs for stroke for recent use were generally higher than those observed for current use for all study medications groups compared with LABA. Compared with recent use of LABA, the adjusted IRR for stroke was 1.79 (95% confidence interval [CI], 1.06-3.00) for recent use of acclidinium bromide and 1.18 (95% CI, 0.50-2.74) for recent use of acclidinium/formoterol.

Comparing each study medication to LABA, adjusted IRRs for AMI, stroke, and MACE for current single and current multiple use of each study medication were similar to those observed for current use that included single and multiple use of the study medications. For acclidinium bromide, the adjusted IRR for AMI was 1.06 (95% CI, 0.72-1.54) for current single use and 1.13 (95% CI, 0.73-1.73) for current multiple use. For acclidinium/formoterol, the adjusted IRR for AMI was 1.03 (95% CI, 0.60-1.77) for current single use and 0.20 (95% CI, 0.03-1.54) for current multiple use. For acclidinium, the adjusted IRR for stroke was 0.78 (95% CI, 0.49-1.24) for current single use and 0.82 (95% CI, 0.52-1.29) for current multiple use. For acclidinium/formoterol, the adjusted IRR for stroke was 0.51 (95% CI, 0.28-0.94) for current single use and 1.04 (95% CI, 0.40-2.72) for current multiple use. For acclidinium bromide, the adjusted IRR for MACE was 0.94 (95% CI, 0.70-1.27) for current single use and 0.99 (95% CI, 0.70-1.38) for current multiple use. For acclidinium/formoterol, the adjusted IRR for MACE was 0.84 (95% CI, 0.54-1.31) for current single use and 0.63 (95% CI, 0.25-1.54) for current multiple use.

When compared with acclidinium bromide, there was no meaningful increased risk of AMI, stroke, or MACE for current use of each study medication. When compared with acclidinium/formoterol, an increased risk of AMI, stroke, and MACE was observed for current use of each study medication. The adjusted IRRs ranged from 1.05 (95% CI, 0.65-1.68) for AMI

to 1.56 (95% CI, 0.95-2.59) for stroke, both for current use of LABA compared with current use of aclidinium/formoterol.

No meaningful increased risk of AMI, stroke, or MACE was observed for short or long duration of current use of any of the study medications compared with current short or long use of LABA, respectively, except for long duration of use of LAMA/LABA versus long duration of use of LABA, which showed an adjusted IRR for AMI of 1.68 (95% CI, 1.10-2.55) and an adjusted IRR for MACE of 1.68 (95% CI, 1.20-2.36).

The study results were consistent across subgroup analyses. In general, IRRs were similar across subgroups, with some variations. No meaningful increased risk with AMI, stroke, or MACE was observed between use of any study medication compared with LABA for any of the subgroups. For some subgroups, precision of effect estimates (IRRs) was low. The results were also consistent across sensitivity analysis using an alternative definition of duration of exposure, an alternative definition of stroke, and analyses using propensity score stratification.

Crude incidence rates for all-cause mortality and for hospitalisation for heart failure were estimated using the updated data. The crude incidence rate per 1,000 person-years for all-cause mortality was 16.4 among users of aclidinium/formoterol and 21.7 among users of aclidinium, and the 95% CIs of these incidence rates overlapped. Use of aclidinium/formoterol was not associated with a meaningful decreased risk of all-cause mortality (adjusted IRR, 0.79; 95% CI, 0.60-1.04) or a meaningful increased risk for hospitalisation for heart failure (adjusted IRR, 1.17; 95% CI, 0.88-1.54) compared with users of aclidinium.

Discussion: Overall, results from this study indicate that the current use of aclidinium, aclidinium/formoterol, tiotropium, other LAMA, LAMA/LABA, or LABA/ICS is not associated with a meaningful increased risk of AMI, stroke, or MACE compared with the use of LABA. The differences in the risks observed in some of the analyses for specific medications, and in the analyses stratified by subgroups of patients, may be explained by random variability from the low number of events and unmeasured confounding.

Results from the current substudy indicate that the risk of all-cause mortality and first-ever hospitalisation for heart failure among users of aclidinium/formoterol is similar to the risk among users of aclidinium, where no increased risk was observed when compared with users of LABA. Therefore, there is no need at this time to update analyses for these endpoints.

Results from the next substudy in the aclidinium cardiovascular post-authorisation safety study (PASS) programme on arrhythmias will provide more information on the cardiovascular safety of aclidinium and other COPD medications.